Some of the names on the move ahead of the open.» Read More
Institutional money will head for the exits in June, Joe Terranova of Virtus Investment Partners says.
The recent run-up in bond yields is being used to justify portfolio changes in preparation for what could be a much different second half.
Couples can avoid financial headaches and relationship heartaches by having a frank discussion of their individual finances long before approaching the altar.
This pro trader explains why gold hasn't bottomed yet.
This pro trader reveals the key levels for the S&P, and explains why Monday's close is so important.
Some of the names on the move ahead of the open.
Health Management Associates rallied hard in the first quarter, and the bulls came back to the hospital operator on Friday.
This is a link to a Bankrate.com story.
Sell in May? They certainly did in emerging markets. But unlike in the old adage, they are likely to sell in June and July too.
With Jeremy Siegel saying the Dow could go to 17,000, investment adviser Michael Yoshikami cautions investors about unbridled euphoria.
Oil prices could extend last week's decline on a patchy global recovery, growing inventories and slack demand, a CNBC survey shows.
Australian equities have fallen almost 7 percent since mid-May, wiping out a sizable portion of the year's gains. But this winter could turn out to be 'wonderland' of opportunities to investors.
The dollar-yen, which has fallen almost 3 percent from a four and half year high in May and is barely hanging on to the 100 mark, is likely to hit 89 by the end of the year, according to one economist.
True, the outlook for the euro zone economy is not great, but there are plenty of good reasons why the euro zone's peripheral equity markets look appealing right now, one expert tells CNBC.
Barclays has been dragged into an international money laundering investigation after U.S. prosecutors discovered that Arthur Budovsky, the founder of digital currency exchange Liberty Reserve, held an account with the British bank.
“I want to tell you about a new cancer fighting biotech name that’s probably not on your radar screen,” said Cramer.
Jim Cramer sees a slew of catalysts on the horizon that could either send stocks surging or tumbling.
CNBC's Melissa Lee and the Options Action traders look at the past week's activity in the options markets, and discuss what they'll be watching in the week ahead.
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
Guess shares surged more than 9 percent Friday following better-than-expected profit despite a significant decline from a year earlier, reports TheSteet.com.